D.A. sheds light on the intricate drug pricing system, revealing how list prices and rebates impact the actual cost to consumers. He discusses the lack of price transparency in healthcare and the monopolistic nature of drug development, highlighting the need for incentives in neglected areas like infectious disease prevention.
